Avrobio Stock Up 16% on Positive Data for Cystinosis Treatment

By Sabela Ojea

Shares of Avrobio on Thursday climbed 16% to 67 cents in pre-market trading Thursday after the company provided positive data from its phase 1/2 clinical trial evaluating a cystinosis gene therapy treatment.

The Cambridge, Mass.-based clinical-stage gene therapy company said the cystinosis program has also received positive regulatory feedback in meetings with the U.S. Food and Drug Administration and U.K. Medicines and Healthcare products Regulatory Agency.

"We are excited about moving this investigational gene therapy closer to patients," said Chief Medical Officer Essra Ridha.

Cystinosis is a rare genetic disorder characterized by the accumulation of an amino acid in different tissues and organs of the body.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

May 18, 2023 07:59 ET (11:59 GMT)

AVROBIO (NASDAQ:AVRO)
Historical Stock Chart
From Apr 2024 to May 2024